www.iajpr.com Page8804 Indo American Journal of Pharmaceutical Research, 2017 ISSN NO: 2231-6876 NANOTECHNOLGY IN CARDIOVASCULAR DISEASES – FUTURE PROSPECTS IN ORO DISPERSABLE DOSAGE FORMS. A. Deevan Paul, P. Nagaraju, T. Mahesh, B. Aruna, E.Reshma Svu College of Pharmaceutical Sciences, S.V. Univerisity, Tirupati. Corresponding author Deevan Paul A. SVU College of Pharmaceutical Sciences, Sri Venkateswara University, Tirupathi. deevan4@gmail.com Copy right © 2017 This is an Open Access article distributed under the terms of the Indo American journal of Pharmaceutical Research, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. ARTICLE INFO ABSTRACT Article history Received 03/06/2017 Available online 15/06/2017 Keywords Engineered Nanoparticles, Unstable Plaque, Coronary Thrombosis, Vascular Injury. Increasing knowledge and treatment of cardiovascular risk factors has led to a decline in mortality rates in developed countries however the problem continues to escalate globally because rates in developing countries are increasing rapidly. The Main Objective of this review is saying about the today’s concept of vulnerable plaque has evolved primarily from the early pioneering work uncovering the pivotal role of plaque rupture and coronary thrombosis as the major cause of acute myocardial infarction and sudden cardiac death. The delivery of the Nanoparticles directly into the blood stream to provide enhanced activity of the unstable plaque in the diagnosis of plaque rupture and may ultimately permit targeted delivery of therapies directly to the site of vascular injury. These nanoparticles as Orodispersable tablets have been successfully used in therapy and there is still no compendia method of their disintegration time. The oral route of administration continues to be the most preferred route due to its diverse advantages including ease of administration, precise dosage, self-medication, versatility and most importantly patient compliance. These methods of formulation shown that development of novel biorelevant methods of ODT’s disintegration time determination is eligible. All these aspects should be taken into consideration during the novel methods development process. Please cite this article in press as Deevan Paul A. et al. Nanotechnolgy in Cardiovascular Diseases – Future Prospects in ORO Dispersable Dosage Forms. Indo American Journal of Pharmaceutical Research.2017:7(05).